Clinical Topics & News
Literature Review
MS bears no effect on certain pregnancy complications, stillbirth, or congenital deformation
Women with MS were more likely to have elective C-sections, induced labor, and babies with low birth weight based on their gestational age.
News
FDA approves intramuscular administration for peginterferon beta-1a in MS
The approval is based on data evaluating bioequivalence and adverse reactions associated with intramuscular administration compared with...
Literature Review
Is the EDSS an adequate outcome measure in secondary progressive MS trials?
Investigators say it may be time to replace as a primary outcome measure an instrument that registers more improvement than is likely possible in...
Literature Review
Stem cell transplant shows long-term benefit in MS
“Autologous hematopoietic stem cell transplant should be considered as a treatment strategy for MS not responding to conventional therapy.”
News
Physicians react: Doctors worry about patients reading their clinical notes
As part of the 21st Century Cures Act, patients will now have the right to see their medical notes.
Literature Review
Which imaging criteria identify progressive forms of MS?
Identification of imaging features associated with primary progressive MS and features that predict evolution from relapsing-remitting MS to...
Literature Review
In MS, serious adverse effects are more common in rituximab versus ocrelizumab
Infection rates are high among reported AEs, and related deaths weren’t uncommon, researchers reported.
Literature Review
Lowering rituximab dose in patients with MS proves safe and effective
Among study participants, no relapses occurred in the year after lowering rituximab dosage to 500 mg.
News
FDA approves ofatumumab (Kesimpta) for relapsing forms of MS
The first FDA-approved self-administered targeted B-cell therapy for MS is delivered via an autoinjector pen.
Clinical Topics & News
MSBase study validates therapy for relapse in secondary progressive MS
An observational cohort study validates medical treatment to reduce disability accumulation in active secondary progressive multiple sclerosis.